Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.

MLA

Clowse, Megan E. B., et al. “Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.” Arthritis & Rheumatology, vol. 69, no. 2, Feb. 2017, pp. 362–75. EBSCOhost, https://doi.org/10.1002/art.39856.

APA

Clowse, M. E. B., Wallace, D. J., Furie, R. A., Petri, M. A., Pike, M. C., Leszczyński, P., Neuwelt, C. M., Hobbs, K., Keiserman, M., Duca, L., Kalunian, K. C., Galateanu, C., Bongardt, S., Stach, C., Beaudot, C., Kilgallen, B., Gordon, C., Batalov, A., Bojinca, M., & Djerassi, R. (2017). Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. Arthritis & Rheumatology, 69(2), 362–375. https://doi.org/10.1002/art.39856

Chicago

Clowse, Megan E. B., Daniel J. Wallace, Richard A. Furie, Michelle A. Petri, Marilyn C. Pike, Piotr Leszczyński, C. Michael Neuwelt, et al. 2017. “Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.” Arthritis & Rheumatology 69 (2): 362–75. doi:10.1002/art.39856.